Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Exact Sciences (EXAS) is anticipated to report a significant year-over-year improvement for the quarter ended June 2025, with an expected loss of $0.02 per share and revenues projected at $774.06 million, a 10.7% increase. Analysts have recently revised EPS estimates 29.73% higher, and with a strong Zacks Earnings ESP of +475.00% and a Zacks Rank of #2 (Buy), EXAS is considered highly likely to surpass consensus EPS estimates. This predictive model, coupled with the company's history of beating expectations in three of the last four quarters, positions EXAS as a compelling candidate for a positive earnings surprise, potentially influencing its stock performance following the August 6 report.

Analysis

Exact Sciences (EXAS) is positioned for a strong quarterly report on August 6, driven by expectations of significant year-over-year fundamental improvement. The consensus outlook projects revenues of $774.06 million, a 10.7% increase, and a dramatically narrowed loss per share of $0.02, which marks a 77.8% improvement from the prior-year quarter. Analyst sentiment has turned increasingly bullish, evidenced by a 29.73% upward revision in the consensus EPS estimate over the last 30 days. This positive momentum is further substantiated by quantitative models, including a Zacks Rank of #2 (Buy) and a highly indicative Earnings ESP of +475.00%. Historically, this combination yields a positive earnings surprise approximately 70% of the time. The company's recent track record, which includes beating EPS estimates in three of the last four quarters, reinforces this expectation. In contrast, industry peer Rhythm Pharmaceuticals (RYTM) faces downward EPS revisions and a negative ESP, highlighting the relative strength of the outlook for EXAS.

Key Decisions for Investors

• Given the combination of a #2 (Buy) rank, a +475.00% Earnings ESP, and significant upward estimate revisions, investors may consider positioning for a potential earnings beat and subsequent share price appreciation.
• While the quantitative signals are strong, the sustainability of any post-earnings rally will depend on management's guidance; therefore, monitor the earnings call for commentary on revenue trajectory and the path to profitability.
• The stock presents a compelling earnings-beat candidate, but investors should recognize that a positive surprise does not guarantee a price increase, and other factors discussed on the call could introduce volatility.